Vimarsana
Biggest News Aggregation in the World

Page 2 - Inducement Plan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Inducement Plan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Inducement Plan Today - Breaking & Trending Today

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Vimarsana News

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

04.06.2024 - CAMBRIDGE, Mass., June 04, 2024 (GLOBE NEWSWIRE) - Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of June 1, 2024, the Compensation Committee of the Board of Directors granted stock ...

Spyre Therapeutics Announces Grants of Inducement Awards - Vimarsana News

Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., June 3, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. , a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations,...

Spyre Therapeutics Announces Grants of Inducement Awards - Vimarsana News

Spyre Therapeutics Announces Grants of Inducement Awards

/PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody...

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Vimarsana News

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Seres Therapeutics, Inc. , a leading microbiome therapeutics company, today announced that on May 1, 2024, the Compensation and Talent Committee of Seres’ board of directors granted inducement...

Spyre Therapeutics Announces Grants of Inducement Awards - Vimarsana News

Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., May 3, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine

Source: wdel.com